17,261 trials
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Primary: ADAMTS-13 Activity Levels — 0.1439; NA; NA; 0.5418 international units(IU)/ml
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
Pancreatic Ductal Adenocarcinoma
Primary: (Part A Experimental Dose Level 0 Only) Safety of the Combination of BMS-813160 Plus Nivolumab Plus Gemcitabine Plus Nab-paclitaxel as Measured by Frequency, Type, and…
Insulin Resistance · Endothelial Dysfunction
Primary: Change in Microvascular Blood Volume (MBV) During Insulin Infusion — 13.16; 11.3 ml/kg
Respiratory Syncytial Virus
Primary: Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 7 Days After First Vaccination — 2; 6; 11; 17 Participants
Chronic Hepatitis D Infection
Primary: Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy — 0.03; -1.78; -1.3; -1.85 log IU/mL
Amyotrophic Lateral Sclerosis · Frontal Temporal Dementia
Primary: The Primary Comparison for Efficacy Will be Based on a Linear Mixed Effects (LME) Model Fit to the ALSFRS-R Data for the Patients Followed Over 36 Weeks. — -0.290…
Diabetes Mellitus, Type 2
Primary: Absolute Change in HbA1c From Baseline to 16 Weeks — -0.23; -0.91; -1.37; -1.79 percentage (%) of HbA1c — p=<0.0001
Fanconi Anemia
Primary: Hematologic Response — 4 Participants
Friedreich Ataxia
Primary: Change From Baseline in Peak Work (in Watts/kg) During Exercise Testing at Week 12 in Part 1 — 0.14; 0.07; -0.09; 0.06 W/kg — p=0.1524
Neoplasms
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants
Breast Cancer
Primary: Number of Patients Experiencing Dose Limiting Toxicity — 10; 0 Participants
Carotid Artery Plaque
Primary: Number of Subjects Who Completed All of the Ultrasound Examinations — 17; 37 Participants
Bladder Cancer · Metastatic Transitional Cell Carcinoma
Primary: Number of Participants Who Were Progression Free at 2 Months — 23; 22 Participants
Allergic Rhinitis · Allergic Rhinitis Due to Grass Pollen · Healthy Volunteers
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants